Faron enters agreement with Abzena for Clevegen
Faron enters into an agreement with Abzena for the manufacture of Clevegen®
Turku, Finland and Cambridge, UK 25 July 2016 - Faron Pharmaceuticals Ltd (AIM: FARN) ("Faron"), a clinical stage biopharmaceutical company, and Abzena plc (AIM: ABZA), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announce that they have entered into an agreement whereby Abzena will manufacture Clevegen®, a novel therapeutic antibody being developed by Faron to reduce immune suppression in cancer. Clevegen may also have the potential to be used in other situations where there is an inadequate immune response, such as in chronic infections or during vaccination.
Clevegen was humanised by Abzena using its Composite Human Antibody® technology. Under the agreement with Faron, Abzena will produce the Master Cell Bank and manufacture the antibody for clinical development under cGMP conditions. This is the first product produced using Abzena's humanisation technology that will also be manufactured by Abzena following its acquisition of PacificGMP in San Diego, USA, in September 2015 to expand its manufacturing offering to Phase I and II clinical studies.
Faron had previously signed an agreement with Selexis to obtain cell clones with high Clevegen production. This collaboration has progressed as planned and the best selected clone will be used by Abzena to produce the Master Cell Bank for Faron.
Markku Jalkanen, CEO of Faron Pharmaceuticals said: "We are very happy to collaborate with Abzena for GMP production of Clevegen to complete our pre-clinical development, and subsequently enter the clinic. We believe that Clevegen can bring an exciting new immune check point target to cancer therapies as it drives conversion of immune suppressive type 2 macrophages to immune active type 1 macrophages."
John Burt, CEO of Abzena commented: "We are pleased to have this opportunity to enable Faron to progress this Abzena Inside antibody towards clinical development through this manufacturing agreement. Following the expansion of our business into the US last year, we have the ability to facilitate our partners' journeys from antibody humanisation to clinical trials."
For more information, please contact:
|
Faron Pharmaceuticals Ltd
|
Abzena plc
|
|
Katja Wallenlind Phone +358 (50) 577 4807
Hume Brophy, PR Mary Clark, Eva Haas, Hollie Vile Phone: +44 207 862 6390 E-mail: faron@humebrophy.com
Cairn Financial Advisers LLP, Nominated Adviser Emma Earl, Tony Rawlinson and Rebecca Anderson Phone: +44 207 148 7900
Panmure Gordon (UK) Limited, Joint Broker Freddy Crossley, Duncan Monteith (Corporate Finance) Tom Salvesen (Corporate Broking) Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker Ranald McGregor-Smith, Francis North Phone: +44 207 659 1234 |
John Burt, Chief executive Officer Julian Smith, Chief Financial Officer Phone: +44 1223 903498
Instinctif Partners Melanie Toyne Sewell, Rozi Morris Phone: +44 207 457 2020 E-mail: abzena@instinctif.com
Cenkos Securities, Nominated Adviser and Broker Ivonne Cantu Phone: +44 207 397 8900
N+1 Singer, Joint Broker Aubrey Powell, Liz Yong Phone: +44 207 496 3000 |
About Clevegen®
Faron's preclinical drug development project Clevegen revolves around Clever-1, a cell surface receptor expressed mainly by endothelial cells and monocytes/macrophages. Clever-1 is involved in cancer growth and spread. The active pharmaceutical ingredient of Clevegen is a humanised anti-Clever-1 antibody.
Clevegen, by binding Clever-1 prevents Tumour Associated Macrophage (TAM) infiltration into a tumour and blocks TAM-to-Tumour cell interaction triggering TAM transformation into tumour supportive cell types. It therefore reduces suppression of the human immune system and converts the whole immune environment around a tumour to immune stimulating allowing a patient's own immune system to combat cancer, known as "immunotherapy". Clevegen has a local tumour effect which also allows the cell-mediated immune response to attack infections in normal tissues and removal of immune suppression locally also limits risk of autoimmune reaction, a potentially severe side effect observed with some immune checkpoint inhibitors. The Directors of Faron believe that Clevegen is well differentiated from competing products as it specifically targets M2 TAMs which facilitate tumour growth, while leaving intact the M1 TAMs which support immune activation against tumours. Clever-1 blocking results especially in activation of Th1 mediated immunity.
About Faron Pharmaceuticals Ltd
Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life- threatening medical condition characterised by widespread inflammation in the lungs. Traumakine is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating and represents a novel immuno-oncology approach. Faron Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
|
• |
Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture. |
|
• |
Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies. |
|
• |
Proprietary site specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals. |
|
• |
Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards. |
For more information, please see www.abzena.com
This information is provided by RNS
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund